By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website –
Check out our openings –

Key Statistics

Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN



Sanofi US 

Bayer Corporation 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotechnologies 

Company News
How Regeneron (REGN) Is Benefiting From Continued Sanofi (SAN.PA) Investments 10/24/2014 7:11:10 AM
Regeneron (REGN), Sanofi (SAN.PA) Begin Pivotal Phase 3 Study For Eczema Drug Dupilumab 10/20/2014 5:41:08 AM
Amgen (AMGN) Files Lawsuit Against Sanofi (SAN.PA) And Regeneron (REGN) For Patent Infringement 10/17/2014 7:47:29 AM
Regeneron (REGN)'s EYLEA® Tops Rivals In Study 10/17/2014 7:23:38 AM
Roche (RHHBY) Lucentis, Regeneron (REGN) Eylea Continue To Battle It Out In Eye Market 10/16/2014 3:06:17 PM
Regeneron Pharmaceuticals, Inc. (REGN) Ranked Number One Biopharmaceutical Employer By Science Magazine For Third Consecutive Year 10/16/2014 1:01:35 PM
Regeneron Pharmaceuticals, Inc. (REGN) Genetics Center Fully Operational, Announces New Collaborations And Key Appointments 10/16/2014 8:00:31 AM
Regeneron Pharmaceuticals, Inc. (REGN) To Report Third Quarter 2014 Financial And Operating Results And Host Conference Call And Webcast On November 4, 2014 10/16/2014 7:22:20 AM
Regeneron Pharmaceuticals, Inc. (REGN) Release: EYLEA® (aflibercept) Injection Receives FDA Approval For Macular Edema Following Retinal Vein Occlusion (RVO) 10/7/2014 7:50:47 AM
Regeneron Pharmaceuticals, Inc. (REGN) Announces EYLEA® (aflibercept) Injection Approved For The Treatment Of Patients With Myopic Choroidal Neovascularization (CNV) In Japan 9/22/2014 7:46:30 AM